Common use of Defined Terms Section Clause in Contracts

Defined Terms Section. Claims 11.1 Combination Product Dispute 1.55 Commercialization Plan 6.2(a) Competing Program 2.5 Confidentiality Agreement 1.20 CTD 1.17 Development Notice 4.7(b) Development Opt-In Notice 4.7(b) Development Participation Costs Dispute 4.7(b) Development Participation Right 4.7(b) Development Plan 4.2 Dispute 14.1 Effective Date Preamble Enforcing Party 9.4(b) GAAP 1.1 GDP 3.2(a)(vi) GlycoMimetics Preamble GlycoMimetics Indemnitees 11.2 GlycoMimetics Inventions 9.1(d)(i) GlycoMimetics Partner 2.2 IFRS 1.1 Indemnified Party 11.3 Indemnifying Party 11.3 Infringement 9.4(a) Initial Development Plan 4.2 Joint Clinical Trial Costs Dispute 4.3(b)(iii) Joint Development Committee (JDC) 3.2(a) Joint Inventions 9.1(d)(iii) Licensed ▇▇▇▇ 9.6(a) Losses 11.1 Manufacturing Technology Transfer Agreement 7.2 NDA 1.54 Party Preamble Pharmacovigilance Agreement 5.8 Product Materials 4.7(a) Region 1.7 Remedial Action 5.9 Reversion Background IP 13.6(f) Reversion Collaboration IP 13.6(f) [***] [***] Royalty Term 8.4(b) Rules 14.2(a) SEC 12.3(c) Study 4.3(b)(i) Supply Agreement 7.1 Term 13.1 Third Party Infringement Actions 9.5 Step-In Rights 9.2(d) VAT 8.10(c)

Defined Terms Section. Claims 11.1 Combination Product Dispute 1.55 Commercialization Plan 6.2(aGenfit Inventions 9.1(c)(i) Competing Program 2.5 Confidentiality Agreement 1.20 CTD 1.17 Development Notice 4.7(b) Development Opt-In Notice 4.7(b) Development Participation Costs Dispute 4.7(b) Development Participation Right 4.7(b) Development Plan 4.2 Dispute 14.1 Effective Date Preamble Enforcing Party 9.4(b) GAAP 1.1 GDP 3.2(a)(vi) GlycoMimetics Preamble GlycoMimetics Indemnitees 11.2 GlycoMimetics Inventions 9.1(d)(i) GlycoMimetics Genfit Partner 2.2 ICC 14.2 IFRS 1.1 Indemnified Party 11.3 Indemnifying Party 11.3 Infringement 9.4(a) Infringement Action 9.5 Initial Development Plan 4.2 Joint Clinical Trial Costs Dispute 4.3(b)(iiiInventions 9.1(c)(iii) Joint Development Steering Committee (JDC) 3.2(a) Joint Inventions 9.1(d)(iii) Licensed ▇▇▇▇ 9.6(a) Losses 11.1 Manufacturing Technology Transfer Agreement 7.2 NDA 1.54 1.53 Party Preamble Pharmacovigilance Agreement 5.8 Product Materials 4.7(a) Region 1.7 4.6 Remedial Action 5.9 Reversion Background IP 13.6(fROFN 2.5(b) Reversion Collaboration IP 13.6(fROFN Exercise Period 2.5(b) [***] [***] ROFN Exercise Notice 2.5(b) ROFN Negotiation Period 2.5(b) ROFN Offer Notice 2.5(b) Royalty Term 8.4(b) Rules 14.2(a) SEC 12.3(c) Study 4.3(b)(i) Supply Agreement 7.1 Term 13.1 Third Party Infringement Actions 9.5 Step-In Rights 9.2(d) Tax Withholding 8.9(b) Term 13.1 Terns Preamble Terns Housemarks 9.6(b) Terns Indemnitees 11.1 Terns Inventions 9.1(c)(ii) Terns Product ▇▇▇▇ 9.6(a) Terns Sublicense Agreement 2.1(c) Third Party Drug Product Supply Agreement 7.2(a)(i) Third Party API Supply Agreement 7.2(b)(i) VAT 8.10(c8.9(d) Working Group 3.5(a)